Why does lung cancer increase in coughing when taking Osimertinib?

Increased coughing is a common side effect in patients with lung cancer receiving osimertinib (Osimertinib). This side effect is usually caused by the drug's effect on the respiratory tract. Osimertinib is a targeted therapy drug that controls lung cancer growth by inhibiting abnormal signaling caused by EGFR mutations. However, it may also affect normal cells and tissues. In the respiratory system, osimertinib may increase airway mucus secretion and trigger a cough response.

Osimertinib may also cause other respiratory-related side effects, such as sore throat, sputum production, dyspnea, etc. These side effects are usually temporary and will be relieved after stopping the drug or adjusting the dose. If coughing increases or other respiratory side effects are severe or prolonged, it is recommended to communicate with your doctor promptly. Your doctor can evaluate your condition and take appropriate action as needed, such as adjusting your medication dose, giving supportive care, or recommending other medications to control your cough.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.